Kaposi Sarcoma Clinical Trial
Official title:
A Phase II Single-arm Study of Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (CKS)
Phase II study of Pembrolizumab plus Lenvatinib in relapsed/refractory Classic Kaposi Sarcoma (CKS). After a screening phase of up to 28 days, each participant will receive study intervention of pembrolizumab plus lenvatinib until reaching a discontinuation criterion: disease progression; unacceptable adverse event(s) (AEs); intercurrent illness that prevents further administration of treatment; participant withdraws consent; pregnancy of participant; non-compliance with study intervention or procedure requirements; or administrative reasons requiring cessation of treatment. After the end of treatment, each participant will be followed for the occurrence of AEs and spontaneously reported pregnancy. Participants who discontinue for reasons other than PD will have post-treatment follow-up for disease status until PD is documented clinically by a team of committed dermatologists, and/or radiographically per RECIST 1.1, a non-study anticancer treatment is initiated, consent is withdrawn, or the participant becomes lost to follow-up. All participants will be followed for overall survival (OS) until death, withdrawal of consent,lost to follow-up, or the end of the study. The end of the study will be when the last participant completes the last study-related telephone call or visit,withdraws from the study, or is lost to follow-up.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06445166 -
Propranolol for the Treatment of Kaposi Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04941274 -
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03160183 -
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
|
||
| Recruiting |
NCT03993106 -
A Study of sEphB4-HSA in Kaposi Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
| Completed |
NCT00395278 -
Development of Serologic Assays for Human Herpes Virus-8
|
||
| Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT03296553 -
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
|
Phase 2 | |
| Recruiting |
NCT04305691 -
Trial of Ixazomib for Kaposi Sarcoma
|
Phase 2 | |
| Completed |
NCT03316274 -
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
|
Early Phase 1 | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
| Recruiting |
NCT06375122 -
Natural History Study of Kaposi Sarcoma
|
||
| Recruiting |
NCT05663502 -
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
|
||
| Recruiting |
NCT05329792 -
L19IL2/L19TNF in Skin Cancer Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
| Completed |
NCT03050788 -
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
|
N/A | |
| Completed |
NCT03404297 -
Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
|
N/A | |
| Terminated |
NCT01412515 -
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06004011 -
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
|
N/A |